Wilson Sonsini tops Life Sciences Law Firm Index for 2nd straight year
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
litigation finance
Navigating the Life Science M&A Savannah
Still recovering from a market correction two years ago, and with a scarcity of attractive targets and ongoing macroeconomic uncertainty, the life sciences dealmaking space is in a state of flux.
Newly United Arnold & Porter Kaye Scholer Surveys Changed Life Sciences Deal Environment
Last year proved a slow one for dealmaking in the life sciences space. But that didn’t stop two of the major legal players in it from consummating one themselves: In November, Arnold & Porter and Kaye Scholer agreed to merge, bringing together two formidable healthcare practices...
Be Classy, Stop Using Monte Carlo Situations Incorrectly
Why not predict pricing correctly, like a true Monegasque?
![By Till Niermann (Own work) [GFDL or CC BY-SA 3.0], via Wikimedia Commons](https://dealbreaker.com/.image/ar_16:9%2Cc_fill%2Ccs_srgb%2Cfl_progressive%2Cg_faces:center%2Cq_auto:good%2Cw_620/MTYxMjc3MTI3OTE5MjE2NjA0/dictionary.jpg)
Terrorist-Attack Litigation Finance Firm Prefers Semantic Defense Strategy
Hedge fund sues over being asked about its 9/11 and NFL concussion-based portfolio.
Peter Thiel Just Invented Revenge Litigation Finance
He's like the Charles Bronson of legal investment capital.
A deeper understanding of corporate venture capital in healthcare (finally!)
It’s time to know more about corporate venture capital because, unlike traditional venture or angel groups, there’s much less insight on corporate VCs and their practices.
Silicon Valley Is A Paradigm For Litigation Finance
If only the Pied Piper boys had known about litigation finance.
Private Equity And Litigation Finance
About a month ago, I discussed the venture capital landscape, and why litigation funders are attractive partners for VCs and VC-backed companies in need of resources to adequately defend their businesses. A similar, but distinct, phenomenon exists in private equity.